LAKE FOREST, Ill., April 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced effectiveness of the appointment of Sigurd (Sig) Kirk to its board of... Read More

LAKE FOREST, Ill., April 01, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc . (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the LD Micro... Read More

Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of $20 to $30 Million LAKE FOREST, Il., March 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a... Read More

LAKE FOREST, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, today announced that it will release fourth... Read More

LAKE FOREST, Ill., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced that effective January 2, 2024, the... Read More

Dan Peisert Stepping Down as CEO Board member Heather Mason Appointed Interim CEO LAKE FOREST, Ill., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a... Read More

LAKE FOREST, Ill., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced today that Sravan Emany has been... Read More

Closed Spectrum Acquisition on July 31, 2023, which diversifies and extends portfolio duration Cash balance at September 30, 2023 of $76.9 million Announces Management Updates LAKE FOREST, Ill., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical... Read More

LAKE FOREST, Ill., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the market... Read More

LAKE FOREST, Ill., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, announced that effective October 4, 2023, the Compensation Committee of the Company’s Board of Directors granted one... Read More

LAKE FOREST, Ill., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, announced that effective August 21, 2023, the Compensation Committee of the Company’s Board of Directors granted one... Read More

LAKE FOREST, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, announced that effective July 31, 2023, the Compensation Committee of the Company’s Board of Directors granted eight... Read More

Second Quarter Net Product Sales Increase 13% Year-Over-Year, Generates $18.6 Million in Cash Flow from Operations Acquisition Expected to be Significantly Accretive to Adjusted EPS in 2024 LAKE FOREST, Ill., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty... Read More

Combination of Assertio’s Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the... Read More

Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill. and BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty... Read More

LAKE FOREST, Ill., July 24, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release second quarter 2023 financial results on Thursday, August 3, 2023, after the market... Read More

LAKE FOREST, Ill., June 26, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company, today announced that it has joined the broad-market Russell 3000 Index as part of the 2023 reconstitution, completed at the close of market on June 23. The annual... Read More

Net Product Sales Increase 18% Year-Over-Year Raises Full Year Outlook to Net Product Sales of $157 to $167 Million, Adjusted EBITDA $90 to $98 Million To Acquire Spectrum Pharmaceuticals in All Stock and CVR Transaction, Expected to be Significantly Accretive to Adjusted EPS and Operating Cash Flow in 2024 LAKE FOREST, Ill.,... Read More

LAKE FOREST, Ill., May 05, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release first quarter 2023 financial results on Tuesday, May 9, 2023, before the market open.... Read More

LAKE FOREST, Ill., April 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the market close.... Read More

Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio’s Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth across All Products Transaction... Read More

SYMPAZAN (clobazam) oral CIV film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and older Oral film delivery from SYMPAZAN ® delivers clobazam to LGS patients with no crushing, no mixing, no prep work LAKE FOREST, Ill., April 24, 2023 (GLOBE NEWSWIRE) --... Read More

LAKE FOREST, Ill., April 07, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, announced that effective April 3, 2023, the Compensation Committee of the Company’s Board of Directors granted two... Read More

Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year Full Year Net Income Increases to $109.6 Million, Non-GAAP Adjusted EBITDA Increases to $101.6 Million Cash Flows from Operations Was $26.7 Million for the Fourth Quarter and $78.6 Million for the Full Year LAKE FOREST, Ill., March 08, 2023 (GLOBE... Read More

LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced the appointment of Howard J. Franklin, MD, as Senior Vice President, Medical. “We see significant... Read More

LAKE FOREST, Ill., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced it has entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with a limited number of... Read More

Year-over-Year Net Product Sales Increased at Least 54% for the Fourth Quarter and 41% for the Full Year Cash Flows from Operations Was at Least $26 Million for the Fourth Quarter and $78 Million for the Full Year To Report Fourth Quarter and Audited Full Year 2022 Financial Results on Wednesday, March 8, 2023 LAKE FOREST,... Read More

LAKE FOREST, Ill., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that Dan Peisert, CEO, and Paul Schwichtenberg, CFO, will host investor meetings Thursday, February 23, 2023... Read More

LAKE FOREST, Ill., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that Dan Peisert, CEO, and Paul Schwichtenberg, CFO, will host investor meetings February 15, 2023 as part... Read More

SYMPAZAN ® (clobazam) oral film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and older Oral film delivery from SYMPAZAN ® delivers clobazam to LGS patients with no crushing, no mixing, no prep work LAKE FOREST, Ill., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company... Read More

LAKE FOREST, Ill., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that U.S. Patent, No. 11541002 for Sympazan® oral film is now listed in the U.S. Food and Drug Administration (“FDA”) publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly... Read More

LAKE FOREST, Ill, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, announced that effective January 3, 2023, the Compensation Committee of the Company’s Board of Directors granted four newly-hired employees a total of 14,804 restricted stock units (“RSUs”) and 16,001 stock options... Read More